Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL

NCT07638787 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Large B-cell Lymphoma

Interventions

DRUG: Polatuzumab Vedotin
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisone
DRUG: Sonrotoclax

Sponsor

Ruijin Hospital